Caring Ambassadors Program

Hepatitis C Newsletter

www.HepCChallenge.org

March 2012

 

Clinical Trials, Cohort Studies, Pilot Studies

 

IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients. Ohnishi M, Tsuge M, Kohno T, et al. J Gastroenterol. 2012 Feb 18. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22350701

A Phase 1, Randomized, Placebo-Controlled, Three-Day, Dose-Ranging Study of GS-5885, an NS5A Inhibitor, in Patients with Genotype 1 Hepatitis C. Lawitz EJ, Gruener D, Hill JM, et al. J Hepatol. 2012 Feb 4. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22314425

 

Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2 to 6: TMC435-C202, a phase IIa, open-label study. Moreno C, Berg T, Tanwandee T, et al. J Hepatol. 2012 Feb 9. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22326470

 

Randomized clinical trial: a pilot study investigating the safety and effectiveness of an escalating dose of peginterferon α-2a monotherapy for 48 weeks compared with standard clinical care in patients with hepatitis C cirrhosis. Tanwar S, Wright M, Foster GR, et al. Eur J Gastroenterol Hepatol. 2012 Feb 14. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22337287

 

A longitudinal cohort study of mucocutaneous drug eruptions during interferon and ribavirin treatment of hepatitis C. Tavakoli-Tabasi S, Bagree A. J Clin Gastroenterol. 2012 Feb;46(2):162-7.

http://www.ncbi.nlm.nih.gov/pubmed/21814144

 

Basic and Applied Science, Pre-Clinical Studies

 

Soluble serum CD81 is elevated in patients with chronic hepatitis C and correlates with alanine aminotransferase serum activity. Welker MW, Reichert D, Susser S, et al. PLoS One. 2012;7(2):e30796. Epub 2012 Feb 15.

http://www.ncbi.nlm.nih.gov/pubmed/22355327

 

Elevated frequency and function of regulatory T cells in patients with active chronic hepatitis C. Tseng KC, Ho YC, Hsieh YH, Lai NS, Wen ZH, Li C, Wu SF. J Gastroenterol. 2012 Feb 28. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22367277

 

High prevalence of autoantibodies to C-reactive protein in patients with chronic hepatitis C infection: association with liver fibrosis and portal inflammation. Sjöwall C, Cardell K, Boström EA, et al. Hum Immunol. 2012 Feb 1. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22333691

 

Sequence Heterogeneity in NS5A of Hepatitis C Virus Genotypes 2a and 2b and Clinical Outcome of Pegylated-Interferon/Ribavirin Therapy. El-Shamy A, Shoji I, Kim SR, et al. PLoS One. 2012;7(2):e30513. Epub 2012 Feb 2.

http://www.ncbi.nlm.nih.gov/pubmed/22319571

 

HIV/HCV Coinfection

 

Deciphering the Interleukin 28B Variants That Better Predict Response to Pegylated Interferon-α and Ribavirin Therapy in HCV/HIV-1 Coinfected Patients. de Castellarnau M, Aparicio E, Parera M, et al. PLoS One. 2012;7(2):e31016. Epub 2012 Feb 6.

http://www.ncbi.nlm.nih.gov/pubmed/22328925

 

Effects of hepatitis C and HIV on cognition in women: data from the Women's Interagency HIV Study. Crystal H, Kleyman I, Anastos K, et al. J Acquir Immune Defic Syndr. 2012 Feb 1;59(2):149-54.

http://www.ncbi.nlm.nih.gov/pubmed/22107817

 

Important Drug-Drug Interactions in HIV-Infected Persons on Antiretroviral Therapy: An Update on New Interactions Between HIV and Non-HIV Drugs. Tseng A, Foisy M. Curr Infect Dis Rep. 2012 Feb;14(1):67-82.

http://www.ncbi.nlm.nih.gov/pubmed/22125049

 

Impact of IL28B gene polymorphisms on interferon-λ3 plasma levels during pegylated interferon-α/ribavirin therapy for chronic hepatitis C in patients coinfected with HIV.

Rallón NI, Soriano V, Naggie S, et al. J Antimicrob Chemother. 2012 Feb 1. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22294646

 

Lack of TGFβ Production by Hepatitis C Virus-Specific T Cells during HCV Acute Phase is Associated with HCV Clearance in HIV co-infection. Harfouch S, Guiguet M, Valantin MA, et al. J Hepatol. 2012 Feb 9. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22326469

 

The Influence of Treatment with Pegylated Interferon-Alfa and Ribavirin on Neutrophil Function and Death in Patients with HIV/HCV Coinfection. Jablonowska E, Wojcik K, Nocun M. Viral Immunol. 2012 Feb 10. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22324288

 

 

 

 

Complementary and Alternative Medicine

 

Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients. Nimer A, Mouch A. World J Gastroenterol. 2012 Feb 28;18(8):800-5.

http://www.ncbi.nlm.nih.gov/pubmed/22371640

 

Serum Vitamin D Levels Are Not Predictive of the Progression of Chronic Liver Disease in Hepatitis C Patients with Advanced Fibrosis. Corey KE, Zheng H, Mendez-Navarro J, Delgado-Borrego A, Dienstag JL, Chung RT; the HALT-C Trial Group. PLoS One. 2012;7(2):e27144. Epub 2012 Feb 16.

http://www.ncbi.nlm.nih.gov/pubmed/22359532

 

Zinc and liver disease. Mohommad MK, Zhou Z, Cave M, Barve A, McClain CJ. Nutr Clin Pract. 2012 Feb;27(1):8-20.

http://www.ncbi.nlm.nih.gov/pubmed/22307488

 

Epidemiology, Diagnostics, and Miscellaneous Works

 

The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. Ann Intern Med. 2012 Feb 21;156(4):271-8.

http://www.ncbi.nlm.nih.gov/pubmed/22351712

 

Routine blood tests to predict liver fibrosis in chronic hepatitis C. Hsieh YY, Tung SY, Lee K, et al. World J Gastroenterol. 2012 Feb 28;18(8):746-53.

http://www.ncbi.nlm.nih.gov/pubmed/22371634

 

Hepatitis A virus vaccination in persons with hepatitis C virus infection: consequences of quality measure implementation. Rowe I, Parker R, Armstrong M, Houlihan D, Mutimer D. Hepatology. 2012 Feb 28. doi: 10.1002/hep.25683. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22371026

 

Future treatment of patients with HCV cirrhosis. Bourlière M, Khaloun A, Wartelle-Bladou C, et al. Liver Int. 2012 Feb;32 Suppl 1:113-9. doi: 10.1111/j.1478-3231.2011.02702.x.

http://www.ncbi.nlm.nih.gov/pubmed/22212581

Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important? Halfon P, Sarrazin C. Liver Int. 2012 Feb;32 Suppl 1:79-87. doi: 10.1111/j.1478-3231.2011.02716.x.

http://www.ncbi.nlm.nih.gov/pubmed/22212577

 

Upper limits of normal for alanine aminotransferase activity in the United States population.  Ruhl CE, Everhart JE. Hepatology. 2012 Feb;55(2):447-54. doi: 10.1002/hep.24725.

http://www.ncbi.nlm.nih.gov/pubmed/21987480

 

Depressive and anxiety disorders in chronic hepatitis C patients: Reliability and validity of the Patient Health Questionnaire. Navinés R, Castellví P, Moreno-España J, et al. J Affect Disord. 2012 Feb 10. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22326842

 

Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk. Litwin AH, Smith BD, Drainoni ML, et al. Dig Liver Dis. 2012 Feb 17. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22342471

 

 

Liver Cancer

 

Transarterial Chemoembolization Plus Sorafenib: A Sequential Therapeutic Scheme for HCV-Related Intermediate-Stage Hepatocellular Carcinoma: A Randomized Clinical Trial. Sansonno D, Lauletta G, Russi S, et al. Oncologist. 2012 Feb 14. [Epub ahead of print]

onteduca V, Sansonno L, Dammacco F.

http://www.ncbi.nlm.nih.gov/pubmed/22334456

 

Viral and host inflammation-related factors that can predict the prognosis of hepatocellular carcinoma. Chen L, Zhang Q, Chang W, Du Y, Zhang H, Cao G. Eur J Cancer. 2012 Feb 9. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22325840

 

Role of fibrogenic markers in chronic hepatitis C and associated hepatocellular carcinoma.

El-Bassiouni NE, Nosseir MM, Madkour ME, et al. Mol Biol Rep. 2012 Feb 9. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22318548